Vertex Pharmaceuticals (VRTX) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free VRTX Stock Alerts $455.34 +12.29 (+2.77%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 7:08 AM | insidertrades.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Sells $1,015,876.80 in StockJune 2 at 6:00 AM | fool.com3 No-Brainer Stocks to Buy in JuneJune 2 at 5:47 AM | fool.com5 Top Stocks to Buy in JuneJune 2 at 4:52 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells $1,478,067.50 in StockJune 1 at 9:09 PM | marketbeat.comAlpha DNA Investment Management LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Alpha DNA Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,947 shJune 1 at 6:52 AM | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Increased to $500.00 by Analysts at BMO Capital MarketsJune 1 at 6:02 AM | gurufocus.comInsider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)May 31 at 4:57 PM | marketbeat.comInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Sells 2,280 Shares of StockVertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) CMO Carmen Bozic sold 2,280 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $445.56, for a total value of $1,015,876.80. Following the completion of the sale, the chief marketing officer now owns 34,659 shares in the company, valued at $15,442,664.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 31 at 12:42 PM | marketbeat.comAtalanta Sosnoff Capital LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Atalanta Sosnoff Capital LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 44.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 175,661 shares of the pharmaceuticalMay 31 at 10:26 AM | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $500.00 at BMO Capital MarketsBMO Capital Markets raised their price objective on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an "outperform" rating in a research report on Friday.May 31 at 8:43 AM | insidertrades.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Charles F. Wagner, Jr. Sells 3,250 SharesMay 31 at 4:52 AM | insidertrades.comInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Sells 1,565 Shares of StockMay 30 at 4:38 PM | marketbeat.comInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells 3,250 Shares of StockVertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) CFO Charles F. Wagner, Jr. sold 3,250 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $454.79, for a total value of $1,478,067.50. Following the completion of the sale, the chief financial officer now owns 50,387 shares in the company, valued at $22,915,503.73. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.May 30 at 3:58 PM | marketbeat.comFiduciary Trust Co Acquires 2,553 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Fiduciary Trust Co raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 54.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,252 shares of the pharmaceutical company's stock after acquiMay 30 at 11:50 AM | seekingalpha.comVertex: Poised For Long-Term Growth Driven By Multiple Pipeline CatalystsMay 30 at 6:04 AM | fool.comShould Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?May 30 at 5:50 AM | fool.comShould Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?May 29, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Lifted by TFO Wealth Partners LLCTFO Wealth Partners LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 44,671.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,134 shares of the pharmaceutical compMay 29, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Sells $715,205.00 in StockVertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) CEO Reshma Kewalramani sold 1,565 shares of the firm's stock in a transaction on Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the completion of the sale, the chief executive officer now owns 121,374 shares in the company, valued at $55,467,918. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.May 28, 2024 | marketbeat.comPortfolio Design Labs LLC Purchases New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Portfolio Design Labs LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,928 shares of theMay 28, 2024 | msn.comCalliditas Therapeutics’ stock surges after $1.1 billion takeover bidMay 28, 2024 | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Lowered to Buy at StockNews.comMay 27, 2024 | investorplace.com3 Underappreciated Biotech Stocks to Buy Now: May 2024May 27, 2024 | marketbeat.comEaton Financial Holdings Company LLC Invests $3.35 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Eaton Financial Holdings Company LLC purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,2May 27, 2024 | marketbeat.comVertex Pharmaceuticals Q1 Earnings TranscriptMay 27, 2024 | americanbankingnews.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Sells $3,168,704.00 in StockMay 26, 2024 | fool.comGot $500? 3 Pharma Stocks to Buy and Hold ForeverMay 26, 2024 | fool.comIs It Too Late to Buy Vertex Pharmaceuticals Stock?May 25, 2024 | marketbeat.comNomura Asset Management Co. Ltd. Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Nomura Asset Management Co. Ltd. cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 150,715 shares of the pharmaceutiMay 25, 2024 | finance.yahoo.comInsider Selling: Director Bruce Sachs Sells Shares of Vertex Pharmaceuticals Inc (VRTX)May 25, 2024 | insidertrades.comBruce I. Sachs Sells 7,073 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) StockMay 25, 2024 | fool.com2 Biotech Stocks to Buy in MayMay 25, 2024 | fool.com3 High-Flying Stocks That Could Soar Even MoreMay 24, 2024 | marketbeat.com1,795 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Skopos Labs Inc.Skopos Labs Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,795 shares of the pharmaceutical company's stoMay 24, 2024 | finance.yahoo.comNew Pain Drug Could Be Big For Vertex Stock As Shares Score BreakoutMay 24, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Bruce I. Sachs Sells 7,073 SharesVertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 24, 2024 | investors.comNew Pain Drug Could Be Big For Vertex Stock As Shares Score BreakoutMay 23, 2024 | marketbeat.com2,650 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by BayBridge Capital Group LLCBayBridge Capital Group LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,650 shares of the pharmaceutical company's stMay 23, 2024 | msn.comWalmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'May 23, 2024 | investorplace.comThe 2030 Millionaire's Club: 3 Biotech Stocks to Buy NowMay 22, 2024 | finance.yahoo.comStocks Step Back After Fed Minutes; Loar, Monday.com, VRTX In FocusMay 22, 2024 | finance.yahoo.comInsider Sale: CEO & President Reshma Kewalramani Sells 15,202 Shares of Vertex ...May 22, 2024 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Ontario Teachers Pension Plan BoardOntario Teachers Pension Plan Board trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 27.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,920 shares of the pharmaceutical company'May 22, 2024 | businesswire.comVertex to Participate in Upcoming June Investor ConferencesMay 22, 2024 | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Sets New 52-Week High at $448.59Vertex Pharmaceuticals (NASDAQ:VRTX) Reaches New 52-Week High at $448.59May 21, 2024 | marketbeat.comOxler Private Wealth LLC Buys New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Oxler Private Wealth LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,784 shares of the pharmaceutical company's stoMay 20, 2024 | marketbeat.comBridger Management LLC Has $19.53 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Bridger Management LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,000 shares of the pharMay 19, 2024 | marketbeat.comNorges Bank Acquires New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Norges Bank bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,042,288 shares of the pharmaceutical company's stock, valued at approximatelyMay 19, 2024 | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Vertex Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday.May 18, 2024 | marketbeat.comSecurian Asset Management Inc. Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Securian Asset Management Inc. lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,324 shares of the pharmaceutical Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. VRTX Media Mentions By Week VRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRTX News Sentiment▼0.800.76▲Average Medical News Sentiment VRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRTX Articles This Week▼3314▲VRTX Articles Average Week Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amgen News Regeneron Pharmaceuticals News Gilead Sciences News Biogen News Alnylam Pharmaceuticals News Royalty Pharma News BeiGene News BioMarin Pharmaceutical News Neurocrine Biosciences News Incyte News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRTX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
